Celltrion plans to support partnered firms by sharing Celltrion's accumulated biologics development expertise, and may, through consultation and discussion, provide development cost or license in the molecule(s). Celltrion is initially focusing on specific therapeutic areas which have the greatest synergy with Celltrion's portfolio - such as autoimmune diseases (rheumatoid arthritis, inflammatory bowel diseases, etc.), breast cancer, lymphoma, and cardiovascular diseases - and is planning to gradually expand its therapeutic areas of interest. Celltrion spokesperson stated that "At 2018 BIO USA, Celltrion is not only promoting the new CDMO business, but is also meeting with potential partnership candidates. Through various "open innovation strategy", including this new CDMO business, Celltrion will expand its new drug pipeline portfolio and take a closer step in becoming a global biopharmaceutical corporation."